Logo image of BMRA

BIOMERICA INC (BMRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BMRA - US09061H4065 - Common Stock

2.4649 USD
-0.08 (-2.96%)
Last: 12/10/2025, 11:09:40 AM
Fundamental Rating

2

Overall BMRA gets a fundamental rating of 2 out of 10. We evaluated BMRA against 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of BMRA is average, but there are quite some concerns on its profitability. BMRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year BMRA has reported negative net income.
BMRA had a negative operating cash flow in the past year.
In the past 5 years BMRA always reported negative net income.
BMRA had a negative operating cash flow in each of the past 5 years.
BMRA Yearly Net Income VS EBIT VS OCF VS FCFBMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

BMRA has a worse Return On Assets (-53.33%) than 68.45% of its industry peers.
Looking at the Return On Equity, with a value of -70.90%, BMRA is in line with its industry, outperforming 43.85% of the companies in the same industry.
Industry RankSector Rank
ROA -53.33%
ROE -70.9%
ROIC N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
BMRA Yearly ROA, ROE, ROICBMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of BMRA (13.02%) is worse than 83.42% of its industry peers.
BMRA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
BMRA Yearly Profit, Operating, Gross MarginsBMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

6

2. Health

2.1 Basic Checks

BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BMRA has been increased compared to 1 year ago.
BMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMRA Yearly Shares OutstandingBMRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
BMRA Yearly Total Debt VS Total AssetsBMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -9.12, we must say that BMRA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BMRA (-9.12) is worse than 79.14% of its industry peers.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.12
ROIC/WACCN/A
WACC8.81%
BMRA Yearly LT Debt VS Equity VS FCFBMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

BMRA has a Current Ratio of 3.48. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.48, BMRA is in the better half of the industry, outperforming 60.96% of the companies in the same industry.
BMRA has a Quick Ratio of 2.61. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.61, BMRA is in the better half of the industry, outperforming 60.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 2.61
BMRA Yearly Current Assets VS Current LiabilitesBMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

0

3. Growth

3.1 Past

BMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.18%, which is quite impressive.
Looking at the last year, BMRA shows a very negative growth in Revenue. The Revenue has decreased by -11.31% in the last year.
BMRA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.51% yearly.
EPS 1Y (TTM)44.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
Revenue 1Y (TTM)-11.31%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-23.63%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMRA Yearly Revenue VS EstimatesBMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
BMRA Yearly EPS VS EstimatesBMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2021 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMRA Price Earnings VS Forward Price EarningsBMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMRA Per share dataBMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOMERICA INC

NASDAQ:BMRA (12/10/2025, 11:09:40 AM)

2.4649

-0.08 (-2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-13 2025-10-13
Earnings (Next)01-12 2026-01-12
Inst Owners3.01%
Inst Owner Change-8.09%
Ins Owners8.81%
Ins Owner Change0%
Market Cap7.27M
Revenue(TTM)4.88M
Net Income(TTM)-3.65M
Analysts85.71
Price TargetN/A
Short Float %1.52%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.66
BVpS1.75
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.33%
ROE -70.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.02%
FCFM N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 2.61
Altman-Z -9.12
F-Score6
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)94.83%
Cap/Depr(5y)109.76%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.31%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-23.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.36%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMERICA INC / BMRA FAQ

What is the fundamental rating for BMRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMRA.


What is the valuation status of BIOMERICA INC (BMRA) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMERICA INC (BMRA). This can be considered as Overvalued.


Can you provide the profitability details for BIOMERICA INC?

BIOMERICA INC (BMRA) has a profitability rating of 0 / 10.